- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Ursodiol
Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring hydrophilic bile acid indicated for the dissolution of radiolucent, non-calcified cholesterol gallstones in patients with a functioning gallbladder, and for the treatment of primary biliary cholangitis (PBC), a chronic progressive cholestatic liver disease. In gallstone disease, ursodiol works by reducing cholesterol secretion into bile and enhancing the formation of liquid crystalline dispersion of cholesterol from the surface of existing gallstones, thereby promoting their gradual dissolution. In primary biliary cholangitis, ursodiol displaces toxic hydrophobic endogenous bile acids from the circulating bile acid pool, protects cholangiocytes and hepatocytes from bile acid-mediated cytotoxicity, stimulates hepatobiliary secretion, and exerts immunomodulatory and anti-apoptotic effects. By reducing exposure of the biliary epithelium to toxic bile acids and slowing disease progression, ursodiol has been shown to improve biochemical markers of cholestasis, delay histological progression, and extend transplant-free survival in patients with PBC.
Usual adult dose: For the dissolution of cholesterol gallstones, the recommended dose is 8 to 10 mg per kilogram of body weight per day, divided into two or three divided doses. This typically corresponds to a total daily dose of approximately 600 mg, administered as 300 mg twice daily with meals. Treatment is usually continued for 6 to 12 months; complete dissolution occurs in approximately 30% to 60% of carefully selected patients with small, floating, radiolucent stones and a patent cystic duct. Ultrasound monitoring should be performed at 6-month intervals to evaluate treatment response. For primary biliary cholangitis, the recommended dose is 13 to 15 mg per kilogram of body weight per day, divided into two to four divided doses administered with food. This typically translates to a total daily dose of 900 mg to 1200 mg, administered as 300 mg three to four times daily. Therapy for PBC is life-long, and prompt initiation at the time of diagnosis is recommended to optimize outcomes. Dose titration may be employed at the start of therapy to minimize gastrointestinal side effects.
Dosage form: Tablets: 150 mg (white to off-white, film-coated, round, biconvex) and 300 mg (white to off-white, film-coated, oval or round, scored). The scored 300 mg tablet allows for dose flexibility, particularly during titration or when weight-based dosing requires intermediate dose adjustments. Capsule formulations may also be available in some jurisdictions.
Onset of action: Following oral administration, ursodiol is absorbed in the small intestine by passive and active transport mechanisms, with peak serum concentrations reached within 1 to 3 hours. In gallstone dissolution therapy, a measurable reduction in biliary cholesterol saturation occurs within the first few weeks of treatment; however, visible reduction in gallstone size on ultrasound typically requires 3 to 6 months of continuous therapy, with complete dissolution taking up to 12 months or longer. In primary biliary cholangitis, improvements in serum alkaline phosphatase, gamma-glutamyl transferase, and alanine aminotransferase levels are generally observed within 4 to 12 weeks of initiating therapy, with maximal biochemical improvement seen by 6 to 12 months.
Duration of action: The elimination half-life of ursodiol is approximately 3.5 to 5.8 days, reflecting extensive enterohepatic recirculation. Following absorption, ursodiol is conjugated with glycine and taurine in the liver, secreted into bile, and reabsorbed from the intestine, creating a continuous enterohepatic cycling process. In PBC, ursodiol becomes the predominant bile acid, representing up to 40% to 60% of the circulating bile acid pool during sustained therapy. Twice-daily or three-times-daily dosing maintains consistent enrichment of the bile acid pool throughout the day.
Alcohol recommendation: Alcohol consumption should be avoided or strictly minimized during treatment with ursodiol. Alcohol is hepatotoxic and can exacerbate underlying liver disease, particularly in patients with primary biliary cholangitis or other cholestatic conditions. Alcohol intake may elevate serum bile acid concentrations and contribute to further hepatocellular damage, potentially antagonizing the hepatoprotective effects of ursodiol. In patients with gallstone disease, alcohol can promote gallbladder stasis and alter biliary lipid composition, potentially interfering with gallstone dissolution therapy. Complete abstinence from alcohol is strongly recommended for all patients with chronic liver disease, including those with PBC, regardless of ursodiol therapy.
Most common side effects: Diarrhea, constipation, dyspepsia, nausea, and abdominal discomfort. Diarrhea is the most frequently reported adverse effect and is generally dose-related; it typically occurs during the initiation of therapy or following dose escalation and often resolves with continued treatment or dose adjustment. Less common adverse effects include back pain, headache, dizziness, and alopecia. Pruritus may initially worsen in a small subset of patients with primary biliary cholangitis during the first few weeks of therapy, though it generally improves as cholestasis parameters normalize. Ursodiol is contraindicated in patients with calcified cholesterol stones, radiopaque stones, non-functioning gallbladders, acute cholecystitis, cholangitis, biliary obstruction, or biliary-gastrointestinal fistula, as these conditions preclude successful dissolution therapy and may require surgical intervention. In PBC patients with decompensated cirrhosis, ursodiol may be less effective, and liver transplantation should be considered when indicated.
Would you like to learn more about Ursodiol for the management of cholesterol gallstones or primary biliary cholangitis?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
